This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
Disease notification – Which conditions are GPs required to report?
The Public Health Act 2010 requires that certain medical conditions be notified to the relevant NSW public health unit -all notifications are kept strictly confidential. All GPs are required to report notifiable conditions to their local PHU on the basis of reasonable clinical suspicion. Case notification should be initiated within 24 hours of diagnosis. Some notifiable conditions include: measles, monkeypox, and pertussis (whooping cough).
GPs must also notify the PHU by phone on 1300 066 055 if the notifiable disease is followed by a phone icon ☎ on the notification form
See National Notifiable Diseases Surveillance System NNDSS fortnightly reports for 22 August to 4 September 2022.
ANIs and RACFs now able to apply for an AIR provider number
Authorised Nurses Immunisers (ANIs) and Residential Care Facilities (RCFs) can now apply for an AIR Provider Number to access the online Australian Immunisation Register (AIR). To apply for an AIR provider number complete the IM004 form and email to MOH-VaccReports@health.nsw.gov.au
ANIs require an ABN to register for their own AIR provider number. ANIs without an ABN can be delegated AIR access from the organisation that employs them or a health professional.
Registered nurses interested in becoming a qualified ANI are encouraged to apply for CESPHN’s Nurse Scholarship to complete the training course and attain this qualification. For more information about the scholarship and to apply, see CESPHN Immunisation website. Applications close 30 September 2022. For further information, see the latest Australian Immunisation Register Update – 19 September 2022.
Monkeypox vaccine – New clinics, referral process and administration advice
Subcutaneous vs Intradermal administration
JYNNEOS monkeypox vaccine was initially administered by subcutaneous injection, however updated clinical guidance from the ATAGI now allows intradermal administration of JYNNEOS monkeypox vaccine in individuals who are not severely immunocompromised and are receiving the vaccine before exposure to monkeypox virus (pre-exposure prophylaxis). AusVaxSafety is monitoring the different vaccine delivery methods and whether there is any impact on side effects.
Referral to Mallett St clinic: GPs can provide referrals to eligible patients – the clinic will take walk-in referrals from GPs or appointments can scheduled by contacting clinic on 0460 013 803 between 9am and 4pm
Referral to Crown St clinic: GPs can directly refer eligible patients for MPX vaccination by calling Sexual Health Info Link (SHIL) on 1800 451 624
Expression of interest: patients can self-register their interest for the MPX vaccine by completing the NSW Health form
Latest MPX webinar:
Watch a recording of CESPHN’s Monkeypox webinar where PHU director Dr Vicky Sheppeard and Infectious Diseases physician Dr Kasha Singh speak about the MPX outbreak situation in CESPHN, vaccination rollout, identification, treatment, and case management.
GPs, practice nurses and pharmacists needed
Researchers at NCIRS are conducting a study to investigate the use of vaccine safety surveillance systems in order to improve and ensure they are fit-for-purpose for the needs of immunisation providers and patients.
GPs, practice nurses and pharmacists are invited to participatein a short telephone or videoconference interview to share your experiences – good, bad or non-existent – with vaccine safety surveillance systems in your daily practice. Participants will be given a voucher for their time and interviews will take place throughout October and November. Registrations close 30 October 2022.
The research was required to understand current attitudes, barriers, motivators and information needs relating to uptake of Influenza vaccines. The findings from the research will be used to inform strategic approaches to address any structural or attitudinal barriers to the uptake of influenza vaccines amongst the general population and key target audiences in future seasons.
Guidance name changed to include all COVID19 vaccine(s), not just mRNA
Updated rates of myocarditis and pericarditis following COVID-19 vaccination by age, gender, and dose
Updated evidence on the long-term outcomes of people with myocarditis or pericarditis following vaccination
Updated recommendations for revaccination in people with a history of myocarditis or pericarditis following vaccination
Third primary dose in severely immunocompromised – updated recommendations
On 23 September 2022, ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised were updated.
What has changed:
ATAGI recommends all individuals aged 6 months and over with certain conditions or on therapies leading to severe immunocompromise to receive a 3rd primary dose of a COVID-19 vaccine.
Novavax can also be used as 3rd primary dose for Immunocompromised populations, however an mRNA COVID-19 vaccine (Pfizer or Moderna) is preferred
Webinars: Upcoming and recorded
COVID-19 response update
About: primary care update on the COVID-19 response and the vaccine rollout – key updates and Q&A
When: Thursday | 29 September 2022 | 12:00pm **note new time**
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
Continuing Professional Development (CPD) annual requirements Below is a snapshot of the continuing professional development (CPD) requirements for doctors, these include annual requirements of: completion of a Professional Development Plan 50 hours CPD each year, split across a range of activities: 25 hours – reviewing performance and measuring outcomes (with five hours minimum…
CESPHN’s Annual Report 2022-23 is now live Central and Eastern Sydney PHN has released its Annual Report 2022-23. The Annual Report is a summary of the key achievements and highlights for the PHN over the financial year. It is split into Improving Care Integration, Improving Practice and Commissioning Services to…